Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill
Overview
Affiliations
Background: Increased cost sharing reduces utilization of prescription drugs, but little evidence demonstrates how this reduction occurs or the factors associated with price sensitivity.
Methods: We conducted a retrospective cohort study of older adults with employer-provided drug coverage from 1997 to 2002 from 31 different health plans. We measured the time until initiation of medical therapy for 17 183 patients with newly diagnosed hypertension, diabetes, or hypercholesterolemia.
Results: For all study conditions, higher copayments were associated with delayed initiation of therapy. In survival models, doubling copayments resulted in large reductions in the predicted proportion of patients initiating pharmacotherapy at 1 and 5 years after diagnosis: for hypertension, 54.8% vs 39.9% at 1 year and 81.6% vs 66.2% at 5 years (P < .001); for hypercholesterolemia, 40.2% vs 31.1% at 1 year and 64.3% vs 53.8% at 5 years (P < .002); and for diabetes, 45.8% vs 40.0% at 1 year and 69.3% vs 62.9% at 5 years (P < .04). However, patients' rate of initiation and sensitivity to copayments strongly depended on their prior experience with prescription drugs. Those without prior drug use (26.1%, 10.4%, and 12.9%) initiated later (833, >1170, and >1402 days later in median time until initiation) and were far more price sensitive (increase of 34.5%, 20.1%, and 27.2% remaining untreated after 5 years when copayments doubled) than those with a history of drug use among patients with newly diagnosed hypertension, hypercholesterolemia, and diabetes, respectively. These results were robust to a wide range of sensitivity analyses.
Conclusions: High cost sharing delays the initiation of drug therapy for patients newly diagnosed with chronic disease. This effect is greater among patients who lack experience with prescription drugs. Policy makers and physicians should consider the effects of benefits design on patient behavior to encourage the adoption of necessary care.
Effects of the Affordable Care Act on Contraception, Pregnancy, and Pregnancy Termination Rates.
Solomon M, Zaritsky E, Warton M, Millman A, Huynh A, Chinnakotla B Obstet Gynecol. 2025; 145(2):196-203.
PMID: 39823363 PMC: 11731061. DOI: 10.1097/AOG.0000000000005796.
Prevalence and predictors of primary nonadherence to medications prescribed in primary care.
Zeitouny S, Cheng L, Wong S, Tadrous M, McGrail K, Law M CMAJ. 2023; 195(30):E1000-E1009.
PMID: 37553145 PMC: 10446155. DOI: 10.1503/cmaj.221018.
The Economic Burden of Out-of-Pocket Expenses for Plastic Surgery Procedures.
Billig J, Chen J, Lu Y, Chung K, Sears E Plast Reconstr Surg. 2020; 145(6):1541-1551.
PMID: 32459783 PMC: 8028743. DOI: 10.1097/PRS.0000000000006847.
Out-of-Pocket Spending for Thumb Carpometacarpal Arthritis: Capitation Matters.
Billig J, Lu Y, Kelley B, Chung K, Sears E Hand (N Y). 2020; 16(6):818-826.
PMID: 32088982 PMC: 8647315. DOI: 10.1177/1558944720906503.
Medicaid Eligibility Expansions May Address Gaps In Access To Diabetes Medications.
Myerson R, Lu T, Tonnu-Mihara I, Huang E Health Aff (Millwood). 2018; 37(8):1200-1207.
PMID: 30080463 PMC: 6642806. DOI: 10.1377/hlthaff.2018.0154.